397 related articles for article (PubMed ID: 19335435)
1. Effects of tacrolimus ointment on the expression of substance P, nerve growth factor, and neurotrophin-3 in atopic dermatitis.
Kim HO; Lee CH; Ahn HK; Park CW
Int J Dermatol; 2009 Apr; 48(4):431-8. PubMed ID: 19335435
[TBL] [Abstract][Full Text] [Related]
2. Tacrolimus decreases the expression of eotaxin, CCR3, RANTES and interleukin-5 in atopic dermatitis.
Park CW; Lee BH; Han HJ; Lee CH; Ahn HK
Br J Dermatol; 2005 Jun; 152(6):1173-81. PubMed ID: 15948978
[TBL] [Abstract][Full Text] [Related]
3. Quantitative analysis of nerve growth factor (NGF) in the atopic dermatitis and psoriasis horny layer and effect of treatment on NGF in atopic dermatitis.
Yamaguchi J; Aihara M; Kobayashi Y; Kambara T; Ikezawa Z
J Dermatol Sci; 2009 Jan; 53(1):48-54. PubMed ID: 18922683
[TBL] [Abstract][Full Text] [Related]
4. Skin and systemic pharmacokinetics of tacrolimus following topical application of tacrolimus ointment in adults with moderate to severe atopic dermatitis.
Undre NA; Moloney FJ; Ahmadi S; Stevenson P; Murphy GM
Br J Dermatol; 2009 Mar; 160(3):665-9. PubMed ID: 19076975
[TBL] [Abstract][Full Text] [Related]
5. 0.03% Tacrolimus ointment applied once or twice daily is more efficacious than 1% hydrocortisone acetate in children with moderate to severe atopic dermatitis: results of a randomized double-blind controlled trial.
Reitamo S; Harper J; Bos JD; Cambazard F; Bruijnzeel-Koomen C; Valk P; Smith C; Moss C; Dobozy A; Palatsi R;
Br J Dermatol; 2004 Mar; 150(3):554-62. PubMed ID: 15030341
[TBL] [Abstract][Full Text] [Related]
6. Reduced dermal infiltration of cytokine-expressing inflammatory cells in atopic dermatitis after short-term topical tacrolimus treatment.
Simon D; Vassina E; Yousefi S; Kozlowski E; Braathen LR; Simon HU
J Allergy Clin Immunol; 2004 Oct; 114(4):887-95. PubMed ID: 15480330
[TBL] [Abstract][Full Text] [Related]
7. Psoralen-ultraviolet A therapy alters epidermal Sema3A and NGF levels and modulates epidermal innervation in atopic dermatitis.
Tominaga M; Tengara S; Kamo A; Ogawa H; Takamori K
J Dermatol Sci; 2009 Jul; 55(1):40-6. PubMed ID: 19443185
[TBL] [Abstract][Full Text] [Related]
8. A multicentre, randomized, double-blind, controlled study of long-term treatment with 0.1% tacrolimus ointment in adults with moderate to severe atopic dermatitis.
Reitamo S; Ortonne JP; Sand C; Cambazard F; Bieber T; Fölster-Holst R; Vena G; Bos JD; Fabbri P; Groenhoej Larsen C;
Br J Dermatol; 2005 Jun; 152(6):1282-9. PubMed ID: 15948994
[TBL] [Abstract][Full Text] [Related]
9. Effect of sequential applications of topical tacrolimus and topical corticosteroids in the treatment of pediatric atopic dermatitis: an open-label pilot study.
Kubota Y; Yoneda K; Nakai K; Katsuura J; Moriue T; Matsuoka Y; Miyamoto I; Ohya Y
J Am Acad Dermatol; 2009 Feb; 60(2):212-7. PubMed ID: 19027990
[TBL] [Abstract][Full Text] [Related]
10. Efficacy and safety of tacrolimus ointment in pediatric Patients with moderate to severe atopic dermatitis.
Singalavanija S; Noppakun N; Limpongsanuruk W; Wisuthsarewong W; Aunhachoke K; Chunharas A; Wananukul S; Akaraphanth R
J Med Assoc Thai; 2006 Nov; 89(11):1915-22. PubMed ID: 17205874
[TBL] [Abstract][Full Text] [Related]
11. Increased nerve growth factor and its receptors in atopic dermatitis: an immunohistochemical study.
Dou YC; Hagströmer L; Emtestam L; Johansson O
Arch Dermatol Res; 2006 Jun; 298(1):31-7. PubMed ID: 16586073
[TBL] [Abstract][Full Text] [Related]
12. Superiority of tacrolimus 0.1% ointment compared with fluticasone 0.005% in adults with moderate to severe atopic dermatitis of the face: results from a randomized, double-blind trial.
Doss N; Reitamo S; Dubertret L; Fekete GL; Kamoun MR; Lahfa M; Ortonne JP
Br J Dermatol; 2009 Aug; 161(2):427-34. PubMed ID: 19416227
[TBL] [Abstract][Full Text] [Related]
13. Topical tacrolimus (FK506) leads to profound phenotypic and functional alterations of epidermal antigen-presenting dendritic cells in atopic dermatitis.
Wollenberg A; Sharma S; von Bubnoff D; Geiger E; Haberstok J; Bieber T
J Allergy Clin Immunol; 2001 Mar; 107(3):519-25. PubMed ID: 11240954
[TBL] [Abstract][Full Text] [Related]
14. Tacrolimus ointment causes inflammatory dendritic epidermal cell depletion but no Langerhans cell apoptosis in patients with atopic dermatitis.
Schuller E; Oppel T; Bornhövd E; Wetzel S; Wollenberg A
J Allergy Clin Immunol; 2004 Jul; 114(1):137-43. PubMed ID: 15241357
[TBL] [Abstract][Full Text] [Related]
15. Mast cells, nerves and neuropeptides in atopic dermatitis and nummular eczema.
Järvikallio A; Harvima IT; Naukkarinen A
Arch Dermatol Res; 2003 Apr; 295(1):2-7. PubMed ID: 12709813
[TBL] [Abstract][Full Text] [Related]
16. Proactive disease management with 0.03% tacrolimus ointment for children with atopic dermatitis: results of a randomized, multicentre, comparative study.
Thaçi D; Reitamo S; Gonzalez Ensenat MA; Moss C; Boccaletti V; Cainelli T; van der Valk P; Buckova H; Sebastian M; Schuttelaar ML; Ruzicka T;
Br J Dermatol; 2008 Dec; 159(6):1348-56. PubMed ID: 18782319
[TBL] [Abstract][Full Text] [Related]
17. A single-center open-label long-term comparison of tacrolimus ointment and topical corticosteroids for treatment of atopic dermatitis.
Neumann E; Amtage D; Bruckner-Tuderman L; Mockenhaupt M
J Dtsch Dermatol Ges; 2008 Jul; 6(7):548-53. PubMed ID: 18248495
[TBL] [Abstract][Full Text] [Related]
18. Proactive treatment of atopic dermatitis in adults with 0.1% tacrolimus ointment.
Wollenberg A; Reitamo S; Girolomoni G; Lahfa M; Ruzicka T; Healy E; Giannetti A; Bieber T; Vyas J; Deleuran M;
Allergy; 2008 Jul; 63(7):742-50. PubMed ID: 18592619
[TBL] [Abstract][Full Text] [Related]
19. Non-melanoma skin cancer in patients with atopic dermatitis treated with topical tacrolimus.
Naylor M; Elmets C; Jaracz E; Rico JM
J Dermatolog Treat; 2005 Aug; 16(3):149-53. PubMed ID: 16096180
[TBL] [Abstract][Full Text] [Related]
20. The comparative effects of tacrolimus and hydrocortisone in adult atopic dermatitis: an immunohistochemical study.
Caproni M; Torchia D; Antiga E; Terranova M; Volpi W; del Bianco E; D'Agata A; Fabbri P
Br J Dermatol; 2007 Feb; 156(2):312-9. PubMed ID: 17223872
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
